From the Doc: Advantages of CyberKnife for Prostate Cancer Treatment

At CyberKnife Center of Chicago, we are dedicated to ensuring patients are well educated before undergoing prostate cancer treatment. Find out how stereotactic body radiation therapy (SBRT) with CyberKnife® can be a treatment option for prostate cancer patients from our medical director Dr. Andy Su.

What sets CyberKnife apart from other treatment options?

The most unique advantage of CyberKnife is the convenience of treatment. CyberKnife is an outpatient procedure that fits into a patient’s current lifestyle. CyberKnife can treat prostate cancer patients in five or fewer sessions, a much shorter time period than conventional forms of radiation therapy. Patients are able to return to their normal routines following each session. The accuracy of treatment may reduce side effects associated with other forms of treatment for prostate cancer. View our treatment options overview here.

How is SBRT with CyberKnife different from conventional radiation therapy?

CyberKnife directly targets the prostate while compensating for normal patient movements, minimizing radiation exposure to surrounding healthy tissue. Treatment time is also significantly shorter given traditional radiation therapy can last up to seven to eight weeks. CyberKnife treatment for prostate cancer is completed within five sessions over a period lasting one to two weeks.

Is SBRT more expensive than other treatment options?

A recent study titled “Cost-Effectiveness Analysis of SBRT Versus IMRT” compared the cost of SBRT and IMRT for treatment of low-to intermediate-risk prostate cancer. The study revealed that on average the cost of SBRT was nearly $14,000 less than IMRT. Learn more about the study here. To find out whether you may be a candidate for CyberKnife treatment, request more information.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.

Follow Us